Board of directors
Dr Jean-Paul Castaigne, MD, MBA
Chairman, President and CEO //
Dr. Castaigne is a senior pharmaceutical executive with extensive
international experience in the pharmaceutical industry. Prior to joining AngioChem, he was
COO and CSO of Conjuchem, and previously he was Vice President, Head of Global R&D at the Fournier
Group in France. In addition, Dr. Castaigne spent eleven years with Novartis in a variety of management
positions, including Corporate Vice President for Canada, President and Managing Director in the
Philippines and Director of Medical and R&D in France. Dr. Castaigne has also worked with CILAG
(J&J) and Sanofi in France.
He received his MD from Paris University in 1975 and held the position of Associate Professor
of oncology and pneumology in 1978. Dr. Castaigne received his advanced diploma in Management of
Business Administration in 1987. Dr. Castaigne is member of the board of the three following
biotech companies: Tranzyme Pharma, Asmacure and Allostera.
Sena K. Biswas, Ph.D.
Managing Director, Life Sciences, VIMAC Ventures //
Dr. Biswas previously acted as a Principal
at TL Ventures, a leading national venture capital firm with over US$1.4 billion under management.
He was founding CEO and/or President of several Life Science companies; most recently at Merrimack
Pharmaceuticals, a network biology-based, drug discovery Company spun out of MIT and Harvard.
His experience also includes Aventis Pharmaceuticals, where he was Director of Business Development
and Bear Stearns & Co. where he was an Associate
in the Healthcare Investment Banking Group.
Martin Godbout, Ph.D.
President and CEO of Genome Canada //
Dr. Godbout is the President and Chief Executive
Officer of Genome Canada since April 2000, and before that he was Senior Vice President at BioCapital
and President and General Manager of Société Innovatech
Québec. Between 1996 and 2004, he was a member of the Board of the “Conseil de la
Science et de la Technologie du Québec” and he has been an Advisory member of several
Canadian biopharmaceutical venture firms such as SGF Santé, Société Innovatech
du Grand Montréal and Royal Bank Ventures Inc. In 2005, Dr. Godbout was appointed Officer
of the Order of Canada. He was also awarded the Grand Prix de Recherche from the Québec
Foundation for Mental Disorders for his previous work on Alzheimer’s disease in 1991 and
the “Prix Summa” in 1994 from the Faculty of Science and Engineering of Université Laval.
In 1994, he also founded BioContact Québec which has become one of the most important biopharmaceutical
symposiums in North America. He holds a B.Sc. in Biochemistry and a Ph.D. in Physiology and Molecular
Endocrinology from Université Laval. In March 2006, Dr. Godbout was shortlisted by the editors
of Nature Biotechnology, as one of twenty nominees who have made the most remarkable and
influential contribution to biotech in the past ten years in the category “Biobusiness in
the rest of the world”.
Jean-François Pariseau, M.Sc., MBA
Director, Venture Capital,
BDC Venture Capital //
Prior to joining BDC, Mr. Pariseau was an Investment Manager with CDP Capital Technology Ventures,
a $2 billion global fund investing in healthcare, information technology and advanced technologies;
and the founding-manager of 2 healthcare companies specializing in regulatory affairs and pharmaceutical-product
distribution. He has invested in companies in the life science sector and actively participated
to their board of directors in both Canada and the United States since 1997. Mr. Pariseau sits
on the board of directors of Osprey Pharmaceuticals Ltd.
|
